Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30277881 | 1.00 | PREP (0.43) | PREPCA12CA1CA9KMT2A | |
| SCHEMBL17838119 | 0.82 | PREP (0.40) | PREPCA12CA1CA9MAPT | |
| SCHEMBL29790285 | 0.81 | CA12 (0.41) | PREPCA12CA1CA9CHRNB2 | |
| SCHEMBL1727022 | 0.81 | CA12 (0.41) | PREPCA12CA1CA9CHRNB2 | |
| SCHEMBL8171650 | 0.79 | KMT2A (0.41) | KMT2ACHRNB2CHRNA4CHRNB1CHRNB4 | |
| SCHEMBL13534994 | 0.79 | CA12 (0.41) | PREPCA12CA1CA9 | |
| SCHEMBL6855170 | 0.79 | CA12 (0.41) | PREPCA12CA1CA9 | |
| SCHEMBL22581908 | 0.79 | CA12 (0.41) | PREPCA12CA1CA9 | |
| SCHEMBL19924498 | 0.79 | ALOX5AP (0.43) | PREPCA12CA1CA9 | |
| SCHEMBL29875070 | 0.79 | ALOX5AP (0.43) | PREPCA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016836-B2 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016836-B2 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-117940407-A | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX生物治疗股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230263760-A1 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | LAPIX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263760-A1 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | LAPIX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11648225-B2 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648225-B2 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3456719-A1 | COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-2922850-B1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20070093535-A1 | Vinyl phenyl derivatives as GLK activators | ASTRAZENECA AB | 2007-04-26 | — | — | US | disclosed |
| US-7199140-B2 | Vinyl phenyl derivatives as GLK activators | ASTRAZENECA AB (SE) | 2007-04-03 | — | — | US | disclosed |
| EP-1406620-B1 | VINYL PHENYL DERIVATIVES AS GLK ACTIVATORS | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20050054715-A1 | Vinyl phenyl derivatives as glk activators | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1406620-A1 | VINYL PHENYL DERIVATIVES AS GLK ACTIVATORS | Astrazeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003000262-A1 | VINYL PHENYL DERIVATIVES AS GLK ACTIVATORS | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263760-A1 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | HLA-DRB1, SLC11A2, CD74 | PREP 1907/4885CA12 3101/4885CA1 3407/4885 |
| US-11648225-B2 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | HLA-DRB1, SLC11A2, CD74 | PREP 1907/4885CA12 3101/4885CA1 3407/4885 |
| US-12016836-B2 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | HLA-DRB1, SLC11A2, CD74 | PREP 1907/4885CA12 3101/4885CA1 3407/4885 |
| US-20050054715-A1 | Vinyl phenyl derivatives as glk activators | GCK, GCKR, GK | PREP 955/4885CA12 3712/4885CA1 3052/4885 |
| US-20070093535-A1 | Vinyl phenyl derivatives as GLK activators | GCK, GCKR, GK | PREP 960/4885CA12 3710/4885CA1 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.